{"id":"W2540205079","doi":"10.1182/blood.v112.11.1576.1576","title":"Tolerability and Efficacy of Bortezomib Added to CVP-R for Previously Untreated Advanced Stage Follicular Lymphoma: Interim Analysis of a Phase II Study by the NCIC Clinical Trials Group.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; Queen's University; Moncton Hospital; Sunnybrook Hospital; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Bortezomib; Interim analysis; Internal medicine; Rituximab; Follicular lymphoma; Surgery; Prednisone; Vincristine; Proteasome inhibitor; Gastroenterology; Adverse effect; Oncology; Clinical trial; Cyclophosphamide; Lymphoma; Chemotherapy; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009265746,0.001807109,0.002492785,0.0005153556,0.0007394035,0.001182652,0.001279078,0.001772652,0.002766854],"category_scores_gemma":[0.004050189,0.000706782,0.002696907,0.0005380361,0.001060835,0.001155305,0.0004699985,0.00395122,0.0008731439],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001145887,"about_ca_system_score_gemma":0.00194145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009375486,"about_ca_topic_score_gemma":0.001155224,"domain_scores_codex":[0.9975817,0.001473425,0.000141922,0.0002520539,0.0002088158,0.0003420474],"domain_scores_gemma":[0.996473,0.0008640568,0.000783566,0.0005778806,0.0002774947,0.001023965],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9088409,0.03809788,0.009905595,0.0001881347,0.002208018,0.0001334067,0.000143519,0.001663682,0.01204794,0.00007201847,0.002101055,0.02459784],"study_design_scores_gemma":[0.3460661,0.6146153,0.02976915,0.00002948245,0.001756788,0.0002231465,0.00004364297,0.001279857,0.00431297,0.0001630544,0.001693613,0.00004684887],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925728,0.001266732,0.0009116058,0.0002302485,0.00009438219,0.002005856,0.001670549,0.000104845,0.001142948],"genre_scores_gemma":[0.9896371,0.0004217971,0.001603845,0.0005026922,0.0001598192,0.002977829,0.003503721,0.00004257041,0.001150601],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009265746,"threshold_uncertainty_score":0.04900259,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06460014398101292,"score_gpt":0.3873754246503171,"score_spread":0.3227752806693042,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}